Table 2 Characteristics of the overall cohort based on the occurrence of orthostatic hypotension or tachycardia syndrome after bone marrow transplant
|  | Patients without OH/POTS (n = 89) | Patients with OH/POTS (n = 47) | p |
|---|---|---|---|
Age, years | 58 [49–63] | 55 [44–63] | 0.26 |
Male sex | 57 (63.3) | 30 (71.4) | 0.43 |
Race | |||
 Black | 24 (26.7) | 9 (21.4) | 0.15 |
 White | 64 (72.2) | 30 (71.4) | |
 Other | 1 (1.1) | 3 (7.1) | |
Hematologic diagnosis | |||
 Multiple myeloma | 22 (24.4) | 10 (23.8) | 0.40 |
 Myelodysplastic syndrome | 7 (7.8) | 2 (4.8) | |
 Myelofibrosis | 7 (7.8) | 2 (4.8) | |
 Acute myeloid leukemia | 19 (21.1) | 8 (19.0) | |
 Acute lymphatic leukemia | 6 (6.7) | 5 (11.9) | |
 Chronic myeloid leukemia | 2 (2.2) | 1 (2.4) | |
 Chronic lymphatic leukemia | 2 (2.2) | 0 | |
 Hodgkin’s lymphoma | 5 (5.6) | 3 (7.1) | |
 Non-Hodgkin’s lymphoma | 12 (13.3) | 8 (19.0) | |
 Aplastic anemia | 4 (4.4) | 0 | |
 Other | 4 (4.4) | 3 (7.2) | |
Donor status | |||
 Related | 19 (21.1) | 9 (21.4) | 0.83 |
 Unrelated | 39 (43.3) | 16 (38.1) | |
BMT type | |||
 Autologous | 32 (35.6) | 17 (40.5) | 0.7 |
 Allogenic | 58 (64.4) | 25 (59.5) | |
CV diseases and risk factors | |||
 Hypertension | 53 (58.9) | 18 (42.9) | 0.1 |
 CAD | 11 (12.2) | 3 (7.1) | 0.55 |
 Heart failure | 22 (24.4) | 6 (14.3) | 0.25 |
 Diabetes mellitus | 16 (17.8) | 4 (9.5) | 0.30 |
 Hypercholesterolemia | 25 (27.8) | 10 (23.8) | 0.68 |
 Atrial fibrillation | 25 (27.8) | 8 (19.0) | 0.39 |
 Chronic kidney disease | 2 (2.2) | 2 (4.8) | 0.59 |
 Smoking | 2 (2.2) | 1 (2.4) | 1.00 |
 Pericarditis | 4 (4.4) | 2 (4.8) | 1.00 |
Treatment with anti-hypertensive drugs prior to BMT | |||
 b-adrenergic blockers | 46 (51.1) | 22 (52.4) | 1.00 |
 Calcium-channel blockers | 21 (23.3) | 8 (19.0) | 0.66 |
 ACE inhibitors | 14 (15.6) | 2 (4.8) | 0.09 |
 ARBs | 4 (4.4) | 2 (4.8) | 1.00 |
 Furosemide/Torsemide | 18 (20.0) | 3 (7.1) | 0.08 |
 Spironolactone | 5 (5.6) | 3 (7.1) | 0.71 |
 None | 24 (27%) | 16 (38) | 0.22 |
Number of anti-hypertensive drugs prior to BMT | |||
 1 | 37 (41.1) | 14 (33.3) | 0.39 |
 2 | 17 (18.9) | 10 (23.8) | |
 3 | 11 (12.2) | 2 (4.8) | |
 4 | 1 (1.1) | 1 (1.1) | |